scholarly journals IgA1 glycosylation in IgA nephropathy: As sweet as it can be

2008 ◽  
Vol 73 (10) ◽  
pp. 1106-1108 ◽  
Author(s):  
J.W. Eijgenraam ◽  
C. van Kooten
Keyword(s):  
Iga Nephropathy ◽  
Iga1 Glycosylation

Loss of the Golgi Matrix Protein 130 Cause Aberrant IgA1 Glycosylation in IgA Nephropathy

2019 ◽  
Vol 49 (4) ◽  
pp. 307-316 ◽  
Author(s):  
Chang Wang ◽  
Muyao Ye ◽  
Qiulan Zhao ◽  
Ming Xia ◽  
Di Liu ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Matrix Protein ◽  
Mononuclear Cells ◽  
Lectin Binding ◽  
Underlying Mechanism ◽  
Sirna Transfection ◽  
Peripheral Blood Mononuclear ◽  
Vicia Villosa Lectin ◽  
Iga1 Glycosylation ◽  
Golgi Matrix

Background: Aberrant O-glycosylation IgA1 production is a major factor in the pathogenesis of IgA nephropathy, but the underlying mechanism is still unclear. IgA1 glycosylation modification is in Golgi, and downregulation of the Golgi peripheral membrane protein Golgi matrix protein 130 (GM130) could lead to glycosylation deficiency. In this study, we aimed to explore the role of GM130 in glycosylate deficiency IgA1 (Gd-IgA1) production. Methods: We enrolled 27 IgA nephropathy patients, 12 patients with chronic tonsillitis, 15 non-IgAN chronic kidney disease patients, and 15 healthy volunteers as healthy control. We explored GM130 expression in Tonsillar tissue by immunofluorescence staining and Western blotting and expression in peripheral blood mononuclear cells (PBMCs) by flow cytometry. The concentration of IgA1 and level of O-glycosylation were determined by ELISA and Vicia Villosa lectin-binding assay. Real-time PCR and Western blot were used to analyze the levels of β1,3-Gal transferase (C1GALT1) and ST6GalNAC2, respectively. To explore the contribution of GM130 in IgA1 O-glycosylation modification, cells were subjected to experiments for evaluation of GM130 silencing by GM130-siRNA transfection. Results: GM130 expression was significantly decreased in tonsil tissues and PBMC of IgAN patients; the expression of C1GALT1 decreased and Gd-IgA1 level increased significantly in patients with IgAN patients. The expression of GM130 was negatively related to Gd-IgA1 production. By siRNA transfection, our results clearly indicated that the downregulation of GM130 can increase IgA1 O-glycosylation deficiency, which is thought to reduce C1GALT1 expression but not affect the expression of ST6GalNAC2. Conclusion: We identified and demonstrated that GM130 plays an important role in IgA1 O-glycans deficiency in IgAN patients, by negatively regulating C1GALT1 expression. We believe that this finding will provide theoretical foundations for a new mechanism of Gd-IgA1 production in IgAN patients.

scholarly journals Aberrant IgA1 Glycosylation Is Inherited in Familial and Sporadic IgA Nephropathy

2008 ◽  
Vol 19 (5) ◽  
pp. 1008-1014 ◽  
Author(s):  
Ali G. Gharavi ◽  
Zina Moldoveanu ◽  
Robert J. Wyatt ◽  
Catherine V. Barker ◽  
Susan Y. Woodford ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Iga1 Glycosylation

IgA1 glycosylation and the pathogenesis of IgA nephropathy

2000 ◽  
Vol 35 (3) ◽  
pp. 551-554 ◽  
Author(s):  
Alice C. Allen ◽  
John Feehally
Keyword(s):  
Iga Nephropathy ◽  
Iga1 Glycosylation

scholarly journals Elevated Plasmaα-Defensins (HNP1–3) Levels Correlated with IgA1 Glycosylation and Susceptibility to IgA Nephropathy

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Yuan-yuan Qi ◽  
Xu-jie Zhou ◽  
Fa-juan Cheng ◽  
Hong Zhang
Keyword(s):  
Iga Nephropathy ◽  
Genome Wide Association Study ◽  
Genome Wide Association ◽  
Healthy Controls ◽  
Pathogenic Role ◽  
Genome Wide ◽  
The Mean ◽  
Iga1 Glycosylation ◽  
Galactose Deficiency

Aim. IgA nephropathy (IgAN) is the most common form of glomerulonephritis. Recent genome-wide association study (GWAS) suggested that DEFA locus (which encodesα-defensins) may play a key role in IgAN.Methods. The levels ofα-defensins in 169 IgAN patients and 83 healthy controls were tested by ELISA.Results. We observed thatα-defensins human neutrophil peptides 1–3 (HNP1–3) in IgAN patients were elevated compared with healthy controls. The mean levels ofα-defensins of 83 healthy controls and 169 IgAN patients were 50 ng/mL and 78.42 ng/mL. When the results were adjusted to the mean levels ofα-defensins of IgAN patients, the percentage of individuals with high levels ofα-defensins increased in IgAN patients (22.5%) compared to healthy controls (9.6%) (p=0.013). The elevation ofα-defensins in IgAN patients was independent of renal function or neutrophil count, which were major sources ofα-defensins in circulation. More importantly, negative correlation was observed between galactose-deficient IgA1andα-defensins.Conclusion. Asα-defensin is a lectin-like peptide, we speculated that it might be involved in IgA galactose deficiency. The data implied that patients with IgAN had higher plasmaα-defensins levels and highα-defensins correlated with IgA galactose deficiency, further suggesting a pathogenic role ofα-defensins in IgAN.

scholarly journals Changes E3 ubiquitin protein ligase 1 gene mRNA expression correlated with IgA1 glycosylation in patients with IgA nephropathy

Renal Failure ◽  
2019 ◽  
Vol 41 (1) ◽  
pp. 370-376 ◽  
Author(s):  
Youxia Liu ◽  
Jie Zheng ◽  
Junya Jia ◽  
Hongfen Li ◽  
Shuiyi Hu ◽  
...  
Keyword(s):  
Mrna Expression ◽  
Iga Nephropathy ◽  
Ubiquitin Protein Ligase ◽  
Iga1 Glycosylation ◽  
Gene Mrna

Treatment of IgA nephropathy

2011 ◽  
Vol 152 (51) ◽  
pp. 2039-2046
Author(s):  
Tibor Vas ◽  
Tibor Kovács ◽  
István Késői ◽  
Balázs Sági ◽  
Péter Degrell ◽  
...  
Keyword(s):  
Renal Function ◽  
Iga Nephropathy ◽  
Treatment Options ◽  
Controlled Trials ◽  
Primary Glomerulonephritis ◽  
Randomized Controlled ◽  
Wide Range ◽  
Iga1 Glycosylation ◽  
Clinical Pictures ◽  
Urinary Abnormalities

IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients. Orv. Hetil., 2011, 152, 2039–2046.

scholarly journals Aberrant IgA1 Glycosylation in IgA Nephropathy: A Systematic Review

PLoS ONE ◽  
2016 ◽  
Vol 11 (11) ◽  
pp. e0166700 ◽  
Author(s):  
Qiang Sun ◽  
Zhenhai Zhang ◽  
Hong Zhang ◽  
Xiaorong Liu
Keyword(s):  
Systematic Review ◽  
Iga Nephropathy ◽  
Iga1 Glycosylation

Interstitial inflammation and the expression of apoptotic modulators in iga nephropathy

Nephrology ◽  
2000 ◽  
Vol 5 (3) ◽  
pp. A114-A114
Author(s):  
Menahem Sa ◽  
Maguire Ja ◽  
Stein‐Oakley A ◽  
Bailey M ◽  
Dowling J ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Interstitial Inflammation
Sign in / Sign up

Export Citation Format

Share Document